Ravulizumab - Alexion AstraZeneca Rare Disease
Alternative Names: ALXN 1210; ALXN 1810; ravulizumab-cwvz; UltomirisLatest Information Update: 12 Jun 2024
At a glance
- Originator Alexion Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; AstraZeneca
- Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemolytic uraemic syndrome; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
- Registered Neuromyelitis optica
- Phase III Acute kidney injury; IgA nephropathy; Thrombotic microangiopathies
- Phase II Lupus nephritis
- Discontinued Acute lung injury; Amyotrophic lateral sclerosis; COVID-19 pneumonia; Dermatomyositis; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 13 Apr 2024 Updated efficacy data from a phase III CHAMPION MG trial in Myasthenia gravis presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024).
- 29 Mar 2024 Phase-III clinical trials in IgA nephropathy (In adults, In the elderly, Treatment-experienced) in Taiwan, South Korea, Japan (IV) (NCT06291376)
- 29 Mar 2024 Phase-III clinical trials in IgA nephropathy (In the elderly, In adults, Treatment-experienced) in USA (IV) (NCT06291376)